RSS

chronic lymphocytic leukaemia (CLL)

Private therapeutics company, Inflection Biosciences, has published preclinical data, demonstrating that its dual mechanism PIM/PI3 kinase inhibitor IBL-202 has promise for the treatment of chronic lymphocytic leukaemia (CLL). more

News

Novartis plans to transition the use of its treatment for certain chronic lymphocytic leukaemia (CLL), Arzerra (ofatumumab), from commercial availability to limited availability via compassionate use programmes in all markets except the US. more

News

The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for Genentech’s venetoclax for the treatment of chronic lymphocytic leukaemia (CLL) more

News